San Diego, California-based biotech Sorrento Therapeutics (SRNE +1.2%) announced on Wednesday that the U.S. Food and Drug Administration (FDA) cleared...
srne stock
The median P/B ratio for stocks in the S&P is just over 3. … Momentum Scorecard. More Info. Zacks Rank...
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease...
